SEC Form 4 · accession 0000911916-15-000306
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew D Dallas
Officer — Chief Financial Officer
Period of report
Aug 4, 2015
Accepted (ET)
Aug 6, 2015 · 2:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $7.56 | Aug 4, 2015 | A | 30,000 | A | — | Aug 4, 2025 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1Options vest as to one-fourth of the shares on August 4, 2016 and as to the remaining shares in a series of 36 successive equal monthly installments upon completion of each additional month of service.